UNLEASHING THE PROMISE OF T-CELL THERAPIES.

DISCOVER ATARA

Cutting-edge science. A fresh approach.

Atara is an allogeneic T-cell immunotherapy company. We're harnessing the natural biology of T cells—our body’s most effective weapon in fighting disease—to develop transformative therapies for patients with cancer and autoimmune conditions.

Off-the-shelf approach

Allogeneic T-cell therapies can be readily available for rapid delivery within days.

Scalable manufacturing

Efficient, robust process with the ability to produce over a thousand doses from one healthy donor.

Highly versatile platform

Potential application for a wide range of disease-causing viral and non-viral targets.

OUR TECHNOLOGY

We’re developing a pipeline of firsts.

Our investigational T-cell therapies target difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. We’re the first company ever to receive an approval for an allogeneic T-cell immunotherapy.

Our Pipeline

In the News

May 5, 2025
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel) READ MORE
November 12, 2024
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress READ MORE
September 3, 2024
Atara Biotherapeutics Announces $36 Million Registered Direct Offering READ MORE

MORE NEWS

Dig deeper.

Explore patient stories, our clinical studies, or visit our investor hub for more information.